{"id":51748,"date":"2022-12-08T19:02:08","date_gmt":"2022-12-08T18:02:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/house-dust-mite-allergy-treatment-global-market-report-2022-an-alarming-surge-in-allergies-worldwide-drives-growth-researchandmarkets-com\/"},"modified":"2022-12-08T19:02:08","modified_gmt":"2022-12-08T18:02:08","slug":"house-dust-mite-allergy-treatment-global-market-report-2022-an-alarming-surge-in-allergies-worldwide-drives-growth-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/house-dust-mite-allergy-treatment-global-market-report-2022-an-alarming-surge-in-allergies-worldwide-drives-growth-researchandmarkets-com\/","title":{"rendered":"House Dust Mite Allergy Treatment Global Market Report 2022: An Alarming Surge in Allergies Worldwide Drives Growth – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “House Dust Mite Allergy Treatment Market By Treatment, By Type, By Route of administration, By Distribution channel: Global Opportunity Analysis and Industry Forecast, 2021-2031”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global house dust mite allergy treatment market was valued at $1,481.2 million in 2021, and is projected to reach $5,189.3 million by 2031, registering a CAGR of 13.4% from 2022 to 2031.\n<\/p>\n

\nThe growth of the global house dust mite allergy treatment market is driven by increasing in-house allergens, rise in awareness among the population about allergic reactions caused due to various types of allergens, and alarming surge in prevalence of allergy diseases.\n<\/p>\n

\nAccording to the Allergy and Asthma Foundation, in March 2020, it was observed that dust mites are the leading causes of in-house allergies. Furthermore, according to the World Health Organization (WHO), in 2020, it was reported that around 70% of allergic reactions are caused due to house dust mite allergen.\n<\/p>\n

\nIn addition, chronic exposure to house dust mites impacts the health of population with asthma, and those who are sensitive and allergic to mites. Thus, the population diagnosed with allergic rhinitis and asthma are more prone to house dust mite allergy. According to the Center for Disease Control and Prevention (CDC), in 2020, it was reported that around 25.2 million population is diagnosed from asthma, globally.\n<\/p>\n

\nAccording to the Thermo Fisher Scientific, it was reported that around 90% of population diagnosed with allergic asthma are sensitized to house dust mite allergens. Moreover, according to the Center for Disease Control and Prevention, in 2020, it was reported that around 60 million population were diagnosed with allergic rhinitis in the U.S. Thus, increase in prevalence of asthma and rhinitis fuels the growth of the house dust mite allergy treatment market.\n<\/p>\n

\nHowever, rise in hygiene practices reduces the occurrence of house dust mite allergy, which hampers the growth of the house dust mite treatment market. Furthermore, lack of proper diagnosis of allergy symptoms caused by house dust mites acts as a key deterrent factor for the global market. On the contrary, increase in awareness among population about various treatments available for allergy diseases is expected to open new avenues for the expansion of the market. This has further encouraged many key players to enter emerging markets, thus offering lucrative opportunities for the market growth.\n<\/p>\n

\nThe global house dust mite treatment market is segmented into treatment, type, route of administration, distribution channel, and region. On the basis of treatment, the market is categorized into antihistamine, immunotherapy, and others. By type, it is bifurcated into prescription and over-the-counter. Depending on route of administration, it is segregated into oral medication and nasal administration. As per distribution channel, it is differentiated into hospital pharmacy, online pharmacy, and retail pharmacy. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.\n<\/p>\n

\nKey Market Segments<\/strong>\n<\/p>\n

\nBy Treatment<\/strong>\n<\/p>\n